Group 1 - CITIC Bank's stock price has declined for six consecutive days, with a total drop of 6.08% during this period, currently trading at 7.40 CNY per share [1] - The bank's market capitalization stands at 411.74 billion CNY, with a trading volume of 473 million CNY and a turnover rate of 0.16% [1] - The main business segments of CITIC Bank include corporate banking (44.58%), retail banking (40.10%), and financial market operations (14.97%) [1] Group 2 - The E Fund's E Fund Baodexin Dividend Mixed A Fund holds 1.136 million shares of CITIC Bank, unchanged from the previous period, representing 3.59% of the fund's net value [2] - The fund has incurred a floating loss of approximately 90,900 CNY today and a total floating loss of 545,300 CNY over the six-day decline [2] - The E Fund Baodexin Dividend Mixed A Fund has a total scale of 269 million CNY and has achieved a year-to-date return of 11.33% [2] Group 3 - The fund manager of E Fund Baodexin Dividend Mixed A is Xu Xiaojie, who has been in the position for over 10 years, with a total asset scale of 1.16 billion CNY [3] - During Xu's tenure, the best fund return was 203.27%, while the worst return was -18.8% [3]

Core Viewpoint - The AI Fund, Everbright Pramerica Dividend Mixed A, reported a profit of 7.3124 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.0451 yuan. The fund's net value growth rate was 2.98%, and its scale reached 269 million yuan by the end of the first half of the year [3]. Fund Performance - As of September 2, the fund's unit net value was 1.947 yuan. The fund manager, Xu Xiaojie, oversees two funds, both of which have shown positive returns over the past year. The highest growth rate among these funds was 64.58% for Everbright Pramerica Health Plus Mixed A, while the lowest was 21.3% for Everbright Pramerica Dividend Mixed A [3]. - The fund's performance over different time frames includes a 12.01% growth rate over the past three months, 15.31% over the past six months, and 21.30% over the past year, ranking 498/607, 403/607, and 542/603 respectively among comparable funds. However, the three-year growth rate was -0.39%, ranking 301/495 [5]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 15.53 times, significantly lower than the industry average of 33.74 times. The weighted average price-to-book (P/B) ratio was about 1.44 times, compared to the industry average of 2.47 times, and the weighted average price-to-sales (P/S) ratio was around 2.53 times, slightly higher than the industry average of 2.07 times [10]. Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.01%, and the weighted average net profit growth rate was 0.02%. The weighted annualized return on equity was 0.09% [17]. Risk and Return Metrics - The fund's Sharpe ratio over the past three years was -0.1408, ranking 341/468 among comparable funds. The maximum drawdown over the past three years was 29.06%, with the largest single-quarter drawdown occurring in Q1 2021 at 17.55% [25][27]. - The fund's average stock position over the past three years was 79.12%, lower than the industry average of 85.36%. The fund reached a peak stock position of 88.83% in the first half of 2020 and a low of 72.82% in the first half of 2024 [30]. Fund Holder Information - As of June 30, 2025, the fund had 12,400 holders, collectively holding 151 million shares. Management personnel held 33,900 shares, accounting for 0.02% of the total, while institutional holdings made up 0.09%, with individual investors holding 99.91% [35]. Top Holdings - The top ten holdings of the fund as of June 30, 2025, included Kelun Pharmaceutical, Zhaoyi Innovation, Bank of China, CITIC Bank, Huahai Pharmaceutical, China Construction Bank, Ningbo Bank, Yangtze Power, China Shenhua Energy, and Chongqing Rural Commercial Bank [40].

Core Viewpoint - The AI Fund Everbright Prudential Dividend Mixed A (360005) reported a profit of 10.48 million yuan for Q2 2025, with a net asset value growth rate of 4.05% during the period [3][17]. Fund Performance - As of July 18, the fund's unit net value was 1.839 yuan, with a one-year return of 6.53%, ranking 521 out of 601 comparable funds [3][4]. - The fund's three-month return was 8.50%, ranking 402 out of 607, and the six-month return was 9.87%, ranking 348 out of 607 [4]. - Over the past three years, the fund's return was -11.71%, ranking 228 out of 468 [4]. Risk Metrics - The fund's Sharpe ratio over the past three years was -0.1408, ranking 341 out of 468 [10]. - The maximum drawdown over the past three years was 29.06%, with the largest single-quarter drawdown occurring in Q1 2021 at 17.55% [12]. Fund Holdings - As of Q2 2025, the fund's top ten holdings included Kelun Pharmaceutical, Zhaoyi Innovation, Bank of China, CITIC Bank, Huahai Pharmaceutical, China Construction Bank, Ningbo Bank, Yangtze Power, China Shenhua, and Chongqing Rural Commercial Bank [21]. - The average stock position over the past three years was 79.12%, compared to the industry average of 85.36% [15].